Navigation Links
Competitive Tech Achieves OTCQX Listing Compliance
Date:11/21/2013

FAIRFIELD, Conn., Nov. 21, 2013 /PRNewswire/ -- Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a pain mitigation biotechnology company, was notified yesterday, Wednesday, November 20, 2013 at 2:24 EST that it had returned to good listing compliance with the OTCQX.

On June 3, 2013, CTI was notified of its non-compliance with the rules and ongoing obligations of a publicly traded OTCQX company as so delineated in Section 3.1.r.(i) of the OTCQX Rules of U.S. Companies. On or about September 27, 2013, Management requested a three month extension to rectify the compliance shortfall due to the fact that there was a new management team in place as of September 26, 2013, which had initiated a corporate reengineering initiative that would rectify the non-compliance issue in short order. OTC Markets verbally agreed to an extension deadline of December 2, 2013.

"Being back in compliance with the OTC Markets is an enormous weight lifted off of CTI's shoulders," said CTI President & CEO Conrad Mir. "The Street has responded well to the recent changes made in the Company, which has contributed to this achievement. We believe this re-compliance may greatly contribute our fourth quarter results."

About the CompanyCompetitive Technologies Inc., (CTI) is a biotechnology company developing and commercializing innovative products and technologies. CTI is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy"® technology developed to treat neuropathic and cancer-derived pain by Professor Giuseppe Marineo.

Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.Contacts:Competitive Technologies, Inc.JV Public RelationsConrad MirJanet VasquezPresident and CEOManaging Directorcmir@competitivetech.netjvasquez@jvprny.com  973.798.8882212.645.5498Scrambler Therapy®: www.scramblertherapy.org/english.htm
Calmare®: www.calmarett.com

www.competitivetech.net

 


'/>"/>
SOURCE Competitive Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Competitive Tech Reports Third Quarter 2013 Results
2. Cambridge Semantics and Linguamatics to Host Webinar on Competitive Intelligence Using Semantic Analysis
3. A*STAR IHPC and IDA to Co-Develop Innovative Cloud-Enabled Technological Solutions for Local ICT Companies to be More Competitive
4. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
5. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
6. PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
7. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
8. Neurovascular/Interventional Neurology Market [Aneurysm Coils, Carotid Stents, Microcatheter, Microguidewire, Liquid Embolic Agents, Cerebral Angioplasty Balloons] - Global Trends & Competitive Analysis - 2017
9. Pre-Clinical Imaging (In vivo) Market - by Systems and Reagents - Competitive Analysis & Global Forecasts to 2017
10. Neurovascular/Interventional Neurology Market: Global Trends & Competitive Analysis - 2017
11. Foot & Ankle Devices Market (2012 – 2017) By Product Type (External Fixation, Internal Fixation, Joint Replacement, Prosthesis, Bracing) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):